Table 1.
Demographic data, dengue severity, co-morbidities, signs and symptoms and laboratory results of patients with and without prophylactic platelet transfusion.
Table 2.
Clinical outcomes of cohort.
Fig 1.
Platelet trend between treatment groups.
Patients receiving platelet transfusion took significantly longer time to recover to platelet count of more than 50,000/mm3.
Fig 2.
Treatment effects after propensity score matching showing that platelet transfusion had no effect on bleeding after adjustment for variables* that may have influenced physician's decision to transfuse platelets.
*Variables: age, year of infection, dengue hemorrhagic fever, severe dengue, diabetes mellitus, cardiac disease, fever day at presentation, presence of any warning signs, temperature, leukocyte count, neutrophil percentage, platelet count, gender, systolic blood pressure < 90mmHg and whether AST, PT and PTT were taken. Clinical bleeding: OR 1.01 (Confidence limit 0.94–1.07); mucosal bleeding: OR 1.03 (Confidence limit 0.98–1.09); internal bleeding: OR 1.01 (Confidence limit 0.97–1.03)
Table 3.
Independent risk factors for clinical bleeding in patients with platelet count <20,000/mm3.